A prospective observational study of nivolumab plus chemotherapy for advanced gastric cancer using CyberOncology (WJOG15922G)
Not Applicable
Recruiting
- Conditions
- nresectable advanced or recurrent gastric or esophagogastric junction cancer
- Registration Number
- JPRN-UMIN000049928
- Lead Sponsor
- West Japan Oncology Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1) Concomitant active malignancies within 3 years prior to registration 2) Active autoimmune disease 3) Requiring systemic corticosteroid or immunosuppressant within 14 days prior to registration 4) Active infection under treatment 5) Pregnant or lactating female 6) Uncontrolled psychiatry disease 7) History of serious allergic reactions 8) Judged inappropriate by the investigators
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie nivolumab's efficacy in advanced gastric cancer with PD-L1 expression?
How does nivolumab plus chemotherapy compare to standard-of-care regimens for unresectable gastric cancer?
Which biomarkers predict response to nivolumab-based immunotherapy in HER2-negative gastric cancer patients?
What are the potential adverse events associated with PD-1 inhibitor combination therapy in advanced gastric cancer?
Are there alternative immune checkpoint inhibitors being studied for esophagogastric junction cancer in Japan?